^
Association details:
Biomarker:BTK C481S
Cancer:Mantle Cell Lymphoma
Drug:edralbrutinib (TG-1701) (BTK inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

TG-1701, a novel irreversible Bruton’s kinase (BTK) inhibitor, cooperates with ublituximab-driven ADCC and ADCP in in vitro and in vivo models of ibrutinib-resistant mantle cell lymphoma

Published date:
05/13/2020
Excerpt:
When compared to ibrutinib, TG-1701 used at high doses retained notable antitumor activity in MCL cells with BTKC481S mutation.